Abstract
Current valve replacement options are limited in their capacity to grow, self-repair, and remodel. Therefore, no ideal valve replacement option exists for the pediatric or young adult population. Researchers have thus turned to tissue engineering, especially with the use of autologous cell sources in order to avoid issues of immunogenicity. The current paradigm uses a scaffold seeded with autologous cells, sometimes expanded and stressed in vitro, prior to implantation. Each step of this process is reviewed here. Biodegradable polymer scaffolds are an attractive option because they can be readily manufactured and provide an off-the-shelf product. However, cell attachment, in vivo degradation performance, and biomechanics are just some of the hurdles to overcome. An alternative to synthetic polymer scaffolds is to decellularize a natural valve which already has the desired structure and functionality. Decellularization reduces immunogenicity and rejection and can be applied to both allografts (human cadaveric) and xenografts (typically porcine). Various decellularization protocols have been tried with successes and failures. Cells that have been then seeded onto the scaffolds include vascular endothelial cells, myofibroblasts, circulating endothelial progenitor cells, and bone-marrow derived stem cells. Bioreactors are becoming increasingly complex with dynamic conditions exerting multiple shear forces on the cells. Meanwhile there is also a movement towards simpler, more practical, hospital-friendly bioreactors. A small series of clinical applications have already been published. Alternative delivery routes, including via transcatheter delivery systems are currently under investigation. Each step in the process of producing autologous bioengineered heart valves has seen growth in the last two decades and gradually researchers are working towards a viable tissue engineered alternative to current prosthetic valves.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Asahara T, Kawamoto A, Masuda H (2011) Concise review: circulating endothelial progenitor cells for vascular medicine. Stem Cells 29:1650–1655
Asahara T, Murohara T, Sullivan A, Silver M, Van Der Zee R, Li T, Witzenbichler B, Schatteman G, Isner JM (1997) Isolation of putative progenitor endothelial cells for angiogenesis. Science 275:964–967
Bader A, Schilling T, Teebken OE, Brandes G, Herden T, Steinhoff G, Haverich A (1998) Tissue engineering of heart valves–human endothelial cell seeding of detergent acellularized porcine valves. Eur J Cardiothorac Surg 14:279–284
Bloch O, Golde P, Dohmen PM, Posner S, Konertz W, Erdbrugger W (2011) Immune response in patients receiving a bioprosthetic heart valve: lack of response with decellularized valves. Tissue Eng Part A 17:2399–2405
Breuer CK, Mettler BA, Anthony T, Sales VL, Schoen FJ, Mayer JE (2004) Application of tissue-engineering principles toward the development of a semilunar heart valve substitute. Tissue Eng 10:1725–1736
Brody S, Pandit A (2007) Approaches to heart valve tissue engineering scaffold design. J Biomed Mater Res B Appl Biomater 83:16–43
Cebotari S, Lichtenberg A, Tudorache I, Hilfiker A, Mertsching H, Leyh R, Breymann T, Kallenbach K, Maniuc L, Batrinac A, Repin O, Maliga O, Ciubotaru A, Haverich A (2006) Clinical application of tissue engineered human heart valves using autologous progenitor cells. Circulation 114:I132–I137
Cebotari S, Tudorache I, Ciubotaru A, Boethig D, Sarikouch S, Goerler A, Lichtenberg A, Cheptanaru E, Barnaciuc S, Cazacu A, Maliga O, Repin O, Maniuc L, Breymann T, Haverich A (2011) Use of fresh decellularized allografts for pulmonary valve replacement may reduce the reoperation rate in children and young adults: early report. Circulation 124:S115–S123
Charitos EI, Takkenberg JJ, Hanke T, Gorski A, Botha C, Franke U, Dodge-Khatami A, Hoerer J, Lange R, Moritz A, Ferrari-Kuehne K, Hetzer R, Huebler M, Bogers AJ, Stierle U, Sievers HH, Hemmer W (2012) Reoperations on the pulmonary autograft and pulmonary homograft after the ross procedure: an update on the German Dutch ross registry. J Thorac Cardiovasc Surg 144:813–821, Discussion 821–3
Converse GL, Buse EE, Hopkins RA (2013) Bioreactors and operating room centric protocols for clinical heart valve tissue engineering. Prog Pediatr Cardiol 35:95–100
Da Costa FD, Dohmen PM, Duarte D, Von Glenn C, Lopes SV, Filho HH, Da Costa MB, Konertz W (2005) Immunological and echocardiographic evaluation of decellularized versus cryopreserved allografts during the Ross operation. Eur J Cardiothorac Surg 27:572–578
Dohmen PM, Lembcke A, Holinski S, Pruss A, Konertz W (2011) Ten years of clinical results with a tissue-engineered pulmonary valve. Ann Thorac Surg 92:1308–1314
Dohmen PM, Lembcke A, Hotz H, Kivelitz D, Konertz WF (2002) Ross operation with a tissue-engineered heart valve. Ann Thorac Surg 74:1438–1442
Driessen-Mol A, Emmert MY, Dijkman PE, Frese L, Sanders B, Weber B, Cesarovic N, Sidler M, Leenders J, Jenni R, Grunenfelder J, Falk V, Baaijens FP, Hoerstrup SP (2014) Transcatheter implantation of homologous “off-the-shelf” tissue-engineered heart valves with self-repair capacity: long-term functionality and rapid in vivo remodeling in sheep. J Am Coll Cardiol 63:1320–1329
Engelmayr GC Jr, Sales VL, Mayer JE Jr, Sacks MS (2006) Cyclic flexure and laminar flow synergistically accelerate mesenchymal stem cell-mediated engineered tissue formation: implications for engineered heart valve tissues. Biomaterials 27:6083–6095
Erdbrugger W, Konertz W, Dohmen PM, Posner S, Ellerbrok H, Brodde OE, Robenek H, Modersohn D, Pruss A, Holinski S, Stein-Konertz M, Pauli G (2006) Decellularized xenogenic heart valves reveal remodeling and growth potential in vivo. Tissue Eng 12:2059–2068
Hibino N, Mcgillicuddy E, Matsumura G, Ichihara Y, Naito Y, Breuer C, Shinoka T (2010) Late-term results of tissue-engineered vascular grafts in humans. J Thorac Cardiovasc Surg 139:431–436, 436 E1-2
Hinderer S, Seifert J, Votteler M, Shen N, Rheinlaender J, Schaffer TE, Schenke-Layland K (2014) Engineering of a bio-functionalized hybrid off-the-shelf heart valve. Biomaterials 35: 2130–2139
Hinton RB, Yutzey KE (2011) Heart valve structure and function in development and disease. Annu Rev Physiol 73:29–46
Hoerstrup SP, Sodian R, Daebritz S, Wang J, Bacha EA, Martin DP, Moran AM, Guleserian KJ, Sperling JS, Kaushal S, Vacanti JP, Schoen FJ, Mayer JE Jr (2000) Functional living trileaflet heart valves grown in vitro. Circulation 102:Iii44–Iii49
Hoffman-Kim D, Maish MS, Krueger PM, Lukoff H, Bert A, Hong T, Hopkins RA (2005) Comparison of three myofibroblast cell sources for the tissue engineering of cardiac valves. Tissue Eng 11:288–301
Juthier F, Vincentelli A, Pincon C, Banfi C, Ennezat PV, Marechaux S, Prat A (2012) Reoperation after the Ross procedure: incidence, management, and survival. Ann Thorac Surg 93:598–604, Discussion 605
Kasimir MT, Rieder E, Seebacher G, Nigisch A, Dekan B, Wolner E, Weigel G, Simon P (2006) Decellularization does not eliminate thrombogenicity and inflammatory stimulation in tissue-engineered porcine heart valves. J Heart Valve Dis 15:278–286, Discussion 286
Le Huu A, Shum-Tim D (2014) Tissue engineering of autologous heart valves: a focused update. Future Cardiol 10:93–104
Leon MB, Smith CR, Mack M, Miller DC, Moses JW, Svensson LG, Tuzcu EM, Webb JG, Fontana GP, Makkar RR, Brown DL, Block PC, Guyton RA, Pichard AD, Bavaria JE, Herrmann HC, Douglas PS, Petersen JL, Akin JJ, Anderson WN, Wang D, Pocock S, Investigators PT (2010) Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N Engl J Med 363:1597–1607
Liu AC, Joag VR, Gotlieb AI (2007) The emerging role of valve interstitial cell phenotypes in regulating heart valve pathobiology. Am J Pathol 171:1407–1418
Masoumi N, Jean A, Zugates JT, Johnson KL, Engelmayr GC Jr (2013a) Laser microfabricated poly(glycerol sebacate) scaffolds for heart valve tissue engineering. J Biomed Mater Res A 101:104–114
Masoumi N, Johnson KL, Howell MC, Engelmayr GC Jr (2013b) Valvular interstitial cell seeded poly(glycerol sebacate) scaffolds: toward a biomimetic in vitro model for heart valve tissue engineering. Acta Biomater 9:5974–5988
Numata S, Fujisato T, Niwaya K, Ishibashi-Ueda H, Nakatani T, Kitamura S (2004) Immunological and histological evaluation of decellularized allograft in a pig model: comparison with cryopreserved allograft. J Heart Valve Dis 13:984–990
Ota T, Taketani S, Iwai S, Miyagawa S, Furuta M, Hara M, Uchimura E, Okita Y, Sawa Y (2007) Novel method of decellularization of porcine valves using polyethylene glycol and gamma irradiation. Ann Thorac Surg 83:1501–1507
Park H, Larson BL, Guillemette MD, Jain SR, Hua C, Engelmayr GC Jr, Freed LE (2011) The significance of pore microarchitecture in a multi-layered elastomeric scaffold for contractile cardiac muscle constructs. Biomaterials 32:1856–1864
Perri G, Polito A, Esposito C, Albanese SB, Francalanci P, Pongiglione G, Carotti A (2012) Early and late failure of tissue-engineered pulmonary valve conduits used for right ventricular outflow tract reconstruction in patients with congenital heart disease. Eur J Cardiothorac Surg 41:1320–1325
Rieder E, Kasimir MT, Silberhumer G, Seebacher G, Wolner E, Simon P, Weigel G (2004) Decellularization protocols of porcine heart valves differ importantly in efficiency of cell removal and susceptibility of the matrix to recellularization with human vascular cells. J Thorac Cardiovasc Surg 127:399–405
Sales VL, Mettler BA, Engelmayr GC Jr, Aikawa E, Bischoff J, Martin DP, Exarhopoulos A, Moses MA, Schoen FJ, Sacks MS, Mayer JE Jr (2010) Endothelial progenitor cells as a sole source for ex vivo seeding of tissue-engineered heart valves. Tissue Eng Part A 16:257–267
Schenke-Layland K, Opitz F, Gross M, Doring C, Halbhuber KJ, Schirrmeister F, Wahlers T, Stock UA (2003) Complete dynamic repopulation of decellularized heart valves by application of defined physical signals-an in vitro study. Cardiovasc Res 60:497–509
Schmidt D, Dijkman PE, Driessen-Mol A, Stenger R, Mariani C, Puolakka A, Rissanen M, Deichmann T, Odermatt B, Weber B, Emmert MY, Zund G, Baaijens FP, Hoerstrup SP (2010) Minimally-invasive implantation of living tissue engineered heart valves: a comprehensive approach from autologous vascular cells to stem cells. J Am Coll Cardiol 56:510–520
Shin’oka T, Matsumura G, Hibino N, Naito Y, Watanabe M, Konuma T, Sakamoto T, Nagatsu M, Kurosawa H (2005) Midterm clinical result of tissue-engineered vascular autografts seeded with autologous bone marrow cells. J Thorac Cardiovasc Surg 129:1330–1338
Shinoka T (2002) Tissue engineered heart valves: autologous cell seeding on biodegradable polymer scaffold. Artif Organs 26:402–406
Shinoka T, Breuer CK, Tanel RE, Zund G, Miura T, Ma PX, Langer R, Vacanti JP, Mayer JE Jr (1995) Tissue engineering heart valves: valve leaflet replacement study in a lamb model. Ann Thorac Surg 60:S513–S516
Shinoka T, Ma PX, Shum-Tim D, Breuer CK, Cusick RA, Zund G, Langer R, Vacanti JP, Mayer JE Jr (1996) Tissue-engineered heart valves. Autologous valve leaflet replacement study in a lamb model. Circulation 94:Ii164–Ii168
Simon P, Kasimir MT, Seebacher G, Weigel G, Ullrich R, Salzer-Muhar U, Rieder E, Wolner E (2003) Early failure of the tissue engineered porcine heart valve synergraft in pediatric patients. Eur J Cardiothorac Surg 23:1002–1006, Discussion 1006
Sodian R, Schaefermeier P, Abegg-Zips S, Kuebler WM, Shakibaei M, Daebritz S, Ziegelmueller J, Schmitz C, Reichart B (2010) Use of human umbilical cord blood-derived progenitor cells for tissue-engineered heart valves. Ann Thorac Surg 89:819–828
Stock UA, Nagashima M, Khalil PN, Nollert GD, Herden T, Sperling JS, Moran A, Lien J, Martin DP, Schoen FJ, Vacanti JP, Mayer JE Jr (2000) Tissue-engineered valved conduits in the pulmonary circulation. J Thorac Cardiovasc Surg 119:732–740
Vincentelli A, Wautot F, Juthier F, Fouquet O, Corseaux D, Marechaux S, Le Tourneau T, Fabre O, Susen S, Van Belle E, Mouquet F, Decoene C, Prat A, Jude B (2007) In vivo autologous recellularization of a tissue-engineered heart valve: are bone marrow mesenchymal stem cells the best candidates? J Thorac Cardiovasc Surg 134:424–432
Weber B, Scherman J, Emmert MY, Gruenenfelder J, Verbeek R, Bracher M, Black M, Kortsmit J, Franz T, Schoenauer R, Baumgartner L, Brokopp C, Agarkova I, Wolint P, Zund G, Falk V, Zilla P, Hoerstrup SP (2011) Injectable living marrow stromal cell-based autologous tissue engineered heart valves: first experiences with a one-step intervention in primates. Eur Heart J 32:2830–2840
Zund G, Breuer CK, Shinoka T, Ma PX, Langer R, Mayer JE, Vacanti JP (1997) The in vitro construction of a tissue engineered bioprosthetic heart valve. Eur J Cardiothorac Surg 11:493–497
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Chung, J., Shum-Tim, D. (2015). Autologous Bioengineered Heart Valves: An Update. In: Suuronen, E., Ruel, M. (eds) Biomaterials for Cardiac Regeneration. Springer, Cham. https://doi.org/10.1007/978-3-319-10972-5_10
Download citation
DOI: https://doi.org/10.1007/978-3-319-10972-5_10
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-10971-8
Online ISBN: 978-3-319-10972-5
eBook Packages: EngineeringEngineering (R0)